Eertink, J. J. http://orcid.org/0000-0002-6094-0016
Arens, A. I. J. http://orcid.org/0000-0001-7066-5372
Huijbregts, J. E. http://orcid.org/0000-0001-9325-2343
Celik, F. http://orcid.org/0000-0002-6486-0435
de Keizer, B. http://orcid.org/0000-0002-6270-9483
Stroobants, S. http://orcid.org/0000-0002-6450-9944
de Jong, D. http://orcid.org/0000-0002-9725-4060
Wiegers, S. E. http://orcid.org/0000-0003-3698-8121
Zwezerijnen, G. J. C. http://orcid.org/0000-0002-9571-9362
Burggraaff, C. N. http://orcid.org/0000-0001-5863-6528
Boellaard, R. http://orcid.org/0000-0002-0313-5686
de Vet, H. C. W. http://orcid.org/0000-0002-5454-2804
Hoekstra, O. S. http://orcid.org/0000-0003-0767-2734
Lugtenburg, P. J. http://orcid.org/0000-0002-6735-8651
Chamuleau, M. E. D. http://orcid.org/0000-0002-0123-9182
Zijlstra, J. M.
,
Funding for this research was provided by:
KWF Kankerbestrijding (#VU 2018-11648)
Article History
Received: 21 May 2021
Accepted: 13 July 2021
First Online: 2 September 2021
Declarations
:
: The HOVON-84 study was approved by the institutional review board of the Erasmus MC (2007–055). The HOVON-130 study was approved by the institutional review board of the VUmc (2014.542). Both studies were performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
: All individual participants included in the HOVON-84 and HOVON-130 studies gave written informed consent to participate in the studies.
: Not applicable.
: J.J.E., A.I.J.A., J.E.H., F.C., B.d.K., S.S., D.d.J., S.E.W., G.J.C.Z., C.N.B. H.C.W.d.V., O.S.H., and R.B. declare no competing financial interests. P.J.L. received research funding from Takeda, Servier, and Roche and received honoraria for advisory boards from Takeda, Servier, Genentech, Genmab, Celgene, and Incyte. M.E.D.C. received research funding from Genmab, Gilead, Celgene, and BMS and received honoraria for advisory boards from Abbvie. J.M.Z. received research funding from Roche and received honoraria for advisory boards from Takeda, Gilead, and Roche.